Trial · NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901, Phase 1, Active not recruiting, ADC Therapeutics S.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7). Trials, record NCT04970901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04970901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- NCT number
- NCT04970901
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 154 participants, actual
- Lead sponsor
- ADC Therapeutics S.A.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
- First posted
- 2021-07-21
- Last updated
- 2026-07-17
- Other registries' IDs
- eudract:2021-001071-16
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) | Day 1 to Day 21 of Cycle 1, where a cycle is 21 days | |
| Primary | Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) | Up to approximately 2 years for Arm C and 3 years for Arms E and F | Frequency and severity of TEAEs and treatment-emergent serious adverse events (TESAEs). TEAEs and TESAEs will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
| Primary | Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay | Up to approximately 1 year | |
| Primary | Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption | Up to approximately 1 year | |
| Primary | Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction | Up to approximately 1 year | |
| Primary | Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements | Baseline up to approximately 1 year | |
| Primary | Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs | Baseline up to approximately 1 year | |
| Primary | Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline up to approximately 1 year | ECOG performance status will be measured on a scale from grades 0-5, where a higher grade indicates a worse outcome. |
| Primary | Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements | Baseline up to approximately 1 year | |
| Secondary | Complete Response Rate (CRR) | Up to approximately 2 years for Arm C and 3 years for Arms E and F |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04970901
GET https://conductscience.org/api/trials/v1/NCT04970901/registered?page=2